Intech Investment Management LLC acquired a new stake in BridgeBio Pharma, Inc. (NASDAQ:BBIO – Free Report) in the 3rd ...

BridgeBio Pharma (NASDAQ:BBIO – Free Report) had its target price upped by HC Wainwright from $43.00 to $49.00 in a research ...

See the new treatment that will break a Pfizer monopoly on a drug for heart disease.

Mizuho Securities analyst Salim Syed has assigned their bullish stance on BBIO stock, giving a Buy rating on November 25.Don't Miss our Black ...

BridgeBio’s Attruby wins approval for transthyretin amyloid cardiomyopathy while the FDA accepts Alnylam’s application for ...

We project BridgeBio's key drug candidate, Attruby (acoramidis), could achieve global sales of around $3.3 billion by 2033. Attruby is an oral drug designed to treat transthyretin amyloid ...

BridgeBio Pharma snagged FDA approval for its rival to Pfizer's heart disease treatment, Vyndaqel. BridgeBio stock catapulted ...

With approval, acoramaidis (Attruby; BridgeBio Pharma) becomes the first agent with a label specifying near-complete ...

With the U.S. FDA approval of Attruby (acoramidis) for transthyretin amyloidosis with cardiomyopathy (ATTR-CM), Bridgebio Pharma Inc. is taking on an industry giant. The next-generation, oral, ...

Acoramidis becomes the second drug ever approved for this condition, based on the results of the ATTRibute-CM trial.

Scotiabank analyst Greg Harrison raised the firm’s price target on BridgeBio (BBIO) to $48 from $45 and keeps an Outperform rating on the ...